by The cancer therapeutics market was valued approximately at US$ 166.5 Bn in 2021 and is projected to hit US$ 365.99 Bn by 2030, registering a CAGR of 9.1% every year.
The global cancer therapeutics market is propelled by numerous factors such as increase in cancer prevalence, surge in focus of vendors on the emerging markets, rise in cancer research and surge in collaboration between pharmaceutical companies. The expanding disposable income, favorable government regulations, growing urban population, and improved infrastructure that favor quality treatments are the major factors that has augmented the growth of the global cancer therapeutics market.
Cancer therapeutics is defined as a process of targeting the changes in the cancer cells that stop or slow down the growth of tumors which is causing cancer in the body of the patient. Gradually, it comprise of chemotherapy, surgery, and radiotherapy. However, there are numerous types of cancer treatment, and therapy application exists which depends up on the stage and type of cancer.
Other cancer treatments include targeted therapy, Immunotherapy, hormone therapy, and stem cell transplant which are under clinical trials and research. The growing prevalence of cancer all around the globe, rise in cancer research and increasing government initiatives for cancer awareness are expected to propel the cancer therapeutics market during the forecast period.
The base year for the study has been considered 2021, the historic year 2017 and 2020, the forecast period considered is from 2022 to 2030. The cancer therapeutics market is analyzed on the basis of value (US$ Million), volume (Unit), and price (US$/Unit).
Download a FREE Sample Copy (Including TOC, List of Tables & Figures, and Chart) @ https://www.precedenceresearch.com/sample/1546
Scope of the Cancer Therapeutics Market
| Report Coverage | Details |
| Market Size | US$ 365.99 Billion by 2030 |
| Growth Rate from 2022 to 2030 | CAGR of 9.1% |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Top Selling Drug, Application, End User, Region |
Report Highlights
- Based on the application, the prostate cancer application segment is anticipated to grow with the highest CAGR throughout the forecast period. However, lung cancer is the dominating segment in the year 2020.
- Based on the top selling drug, the Revlimid segment occupied the largest share in the cancer therapeutics market, owing to the fact that it received a breakthrough therapy designation. Revlimid (lenalidomide) belongs to the class of immunomodulatory drugs. It is an oral cancer drug indicated for multiple myeloma treatment. Revlimid functions against cancer cells partly by impacting the immune system.
- Based on end user, cancer and radiation therapy centers is the dominating segment of cancer therapeutic market however growing demand towards specialty treatment owing to rising disposable income and health concerns the specialty treatment segment is the fastest growing segment during the forecast period.
Regional Snapshot
North America comprises of a market share of more than 35% and has dominated the global cancer therapeutics market in the year 2020. Owing to increase in adoption of cancer therapeutics and heavy funding by various organizations has presented a lucrative growth opportunities for the key market players. In addition, the growing government investments in the urbanization, infrastructural developments, electrification, and development of IT and telecommunications infrastructure has prominently contributed towards the growth of the North America cancer therapeutics Market.
However, stomach, lung, colorectum, esophagus and liver are the most common types of cancer in China. The rising occurrence of cancer burden and thus, cancer therapies is owing to a number of factors including but not limited to aging, population growth, environmental pollution, and unhealthy eating habits. Moreover, in particular, cigarette smoking, has also continued to be dominant reason. All these factors has made the Asia-Pacific region, the fastest-growing cancer therapeutics market.
Europe was the second-largest market in 2020. The affluence in regulatory approval for novel cancer therapy in Europe, rising prevalence of cancer, an increase in healthcare spending for cancer, and strong R&D initiatives from key players. Furthermore, according to the Global Cancer Observatory, the number of the deaths exceeded 1.9 million due to cancer and the number of new cancer cases for the year 2018 was 4.2 million and in European region.
There are more factors responsible for the rising incidence of cancer in Europe, such as obesity, unhealthy lifestyles and inappropriate diet, and lack of physical activity. Thus, the growing incidence and prevalence of cancer are likely to drive the growth of the cancer therapeutics market in European region during the forecast period.
Market Dynamics
Driver
Increasing penetration of the internet
The major factors driving the growth of the market are the increase in R&D and the rising prevalence of various types of cancers. Also, targeted therapy is gaining significance due to its particularity toward cancer cells while sparing the toxin to off- target cells. Bone cancer is the most prevalent cancer in the region, and the rising incidences of this cancer and effective treatment of the targeted therapy in bone cancer cases are boosting the market growth.
As per a recent 2018 study presented at 11th European Bone Cancer Conference, expansive surgery involving mastectomy and removal of several lymph bumps can be safely avoided for further women with some types of bone cancer, if they receive targeted medicines before surgery. Thus, owing to the rising approvals from regulatory bodies and an increase in the incidences of all types of cancer, the market is anticipated to witness a high growth rate over the cast period.
Restraint
Adverse effects related to cancer therapeutics and high costs associated with oncology drugs
Cancer treatments and cancer can beget side goods. Side goods are problems that do when treatment affects healthy tissues or organs. There are multiple problems associated with cancer therapy which includes appetite loss, Anemia, bleeding and bruising (thrombocytopenia), distraction, constipation, diarrhea, edema ( lump), fertility issues in boys and men, fatigue, fertility issues in girls and women, hair loss (alopecia), flu-suchlike symptoms, infection and neutropenia, memory or attention problems, lymphedema, mouth and throat problems, nausea and vomiting, whim-whams problems, immunotherapy and organ- related inflammation, sexual health issues in women, sleep problems, skin and nail changes, urinary and bladder problems.
In addition, costs for cancer care were estimated to be $190.2 billion in 2015 and $208.9 billion in 2020, an increase of 10% that’s only due to the aging and growth of the U.S. population. These cost estimates include cancer-attributable costs for medical services and oral prescription medicines. National medical services costs were largest female breast, lung, colorectal, and prostate cancers and non-Hodgkin lymphomas. The national costs reflect frequency of the complaint, treatment patterns, and costs for different types of care. Thus, adverse effects related to cancer therapy and high costs associated with oncology medicines leads the patient to step back from cancer remedy which impede the growth of the cancer therapeutics request.
Read More@ High Performance Computing Market Size to Touch $ 64.65 Billion By 2030
Opportunity
Upsurge in demand for personalized medicine
Cancer is a ruinous disease that takes the lives of hundreds of thousands of patient every year. Due to standard treatments, disease heterogeneity, such as chemotherapy or radiation, are effective in only a subset of the patient population. Tumors have different beginning inheritable causes and may express different proteins in one case versus another. This essential variability of cancer lends itself to the growing field of perfection and substantiated drug (PPM).
There are numerous ongoing efforts to acquire PPM data in order to characterize molecular differences between tumors. Some PPM products are formerly available to link these differences to an effective drug. It’s clear that PPM cancer treatments can result in immense patient benefits, and companies and nonsupervisory agencies have begun to fete this. Thus, substantiated drugs are likely to boost the request growth during the cast period.
Challenge
Lack of adequate infrastructure
Cancer is clearly the most deadly disease in the advanced world as one in three people develop cancer during their lifetime. The cure for cancer is like the Holy Grail since utmost of the being treatments aren’t effective enough to give full protection from this disease. In recent times the burgeoning of proteomic, sophisticated genomic, and bioinformatics ways has made it possible for the healthcare industry to get a glimpse of the intricate interplay of multitudinous cellular genes and nonsupervisory inheritable rudiments that are responsible for the incarnation of cancerous phenotypes.
With the use of ultramodern genomic technologies the industry is now beginning to understand the enormous complexity of cancer. Still there are many success stories as far as the treatment of cancer is concerned. For instance the treatments of carcinoma and leukemia have been established and proved to be satisfactory. Despite occasional successes the treatment for utmost cancers is still a long way from reality. In this tract, the industry addressed several reasons for the difficulties in cancer treatment which is challenging the market.
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Cancer Therapeutics Market
5.1. COVID-19 Landscape: Cancer Therapeutics Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Cancer Therapeutics Market, By Top Selling Drugs
8.1. Cancer Therapeutics Market, by Top Selling Drugs Type, 2021-2030
8.1.1. Revlimid
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Avastin
8.1.2.1. Market Revenue and Forecast (2019-2030)
8.1.3. Herceptin
8.1.3.1. Market Revenue and Forecast (2019-2030)
8.1.4. Rituxan
8.1.4.1. Market Revenue and Forecast (2019-2030)
8.1.5. Opdivo
8.1.5.1. Market Revenue and Forecast (2019-2030)
8.1.6. Gleevec
8.1.6.1. Market Revenue and Forecast (2019-2030)
8.1.7. Velcade
8.1.7.1. Market Revenue and Forecast (2019-2030)
8.1.8. Imbruvica
8.1.8.1. Market Revenue and Forecast (2019-2030)
8.1.9. Ibrance
8.1.9.1. Market Revenue and Forecast (2019-2030)
8.1.10. Zytiga
8.1.10.1. Market Revenue and Forecast (2019-2030)
8.1.11. Alimta
8.1.11.1. Market Revenue and Forecast (2019-2030)
8.1.12. Xtandi
8.1.12.1. Market Revenue and Forecast (2019-2030)
8.1.13. Tarceva
8.1.13.1. Market Revenue and Forecast (2019-2030)
8.1.14. Perjeta
8.1.14.1. Market Revenue and Forecast (2019-2030)
8.1.15. Temodar
8.1.15.1. Market Revenue and Forecast (2019-2030)
8.1.16. Others
8.1.16.1. Market Revenue and Forecast (2019-2030)
Chapter 9. Global Cancer Therapeutics Market, By Application
9.1. Cancer Therapeutics Market, by Application, 2021-2030
9.1.1. Blood Cancer
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Lung Cancer
9.1.2.1. Market Revenue and Forecast (2019-2030)
9.1.3. Colorectal Cancer
9.1.3.1. Market Revenue and Forecast (2019-2030)
9.1.4. Prostate Cancer
9.1.4.1. Market Revenue and Forecast (2019-2030)
9.1.5. Breast Cancer
9.1.5.1. Market Revenue and Forecast (2019-2030)
9.1.6. Cervical Cancer
9.1.6.1. Market Revenue and Forecast (2019-2030)
9.1.7. Head and Neck Cancer
9.1.7.1. Market Revenue and Forecast (2019-2030)
9.1.8. Glioblastoma
9.1.8.1. Market Revenue and Forecast (2019-2030)
9.1.9. Malignant Meningioma
9.1.9.1. Market Revenue and Forecast (2019-2030)
9.1.10. Mesothelioma
9.1.10.1. Market Revenue and Forecast (2019-2030)
9.1.11. Melanoma
9.1.11.1. Market Revenue and Forecast (2019-2030)
9.1.12. Others
9.1.12.1. Market Revenue and Forecast (2019-2030)
Chapter 10. Global Cancer Therapeutics Market, By End User
10.1. Cancer Therapeutics Market, by End User, 2021-2030
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2019-2030)
10.1.2. Specialty Clinics
10.1.2.1. Market Revenue and Forecast (2019-2030)
10.1.3. Cancer and Radiation Therapy Centers
10.1.3.1. Market Revenue and Forecast (2019-2030)
Chapter 11. Global Cancer Therapeutics Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)
11.1.2. Market Revenue and Forecast, by Application (2019-2030)
11.1.3. Market Revenue and Forecast, by End User (2019-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)
11.1.4.2. Market Revenue and Forecast, by Application (2019-2030)
11.1.4.3. Market Revenue and Forecast, by End User (2019-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)
11.1.5.2. Market Revenue and Forecast, by Application (2019-2030)
11.1.5.3. Market Revenue and Forecast, by End User (2019-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)
11.2.2. Market Revenue and Forecast, by Application (2019-2030)
11.2.3. Market Revenue and Forecast, by End User (2019-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)
11.2.4.2. Market Revenue and Forecast, by Application (2019-2030)
11.2.4.3. Market Revenue and Forecast, by End User (2019-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)
11.2.5.2. Market Revenue and Forecast, by Application (2019-2030)
11.2.5.3. Market Revenue and Forecast, by End User (2019-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)
11.2.6.2. Market Revenue and Forecast, by Application (2019-2030)
11.2.6.3. Market Revenue and Forecast, by End User (2019-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)
11.2.7.2. Market Revenue and Forecast, by Application (2019-2030)
11.2.7.3. Market Revenue and Forecast, by End User (2019-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)
11.3.2. Market Revenue and Forecast, by Application (2019-2030)
11.3.3. Market Revenue and Forecast, by End User (2019-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)
11.3.4.2. Market Revenue and Forecast, by Application (2019-2030)
11.3.4.3. Market Revenue and Forecast, by End User (2019-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)
11.3.5.2. Market Revenue and Forecast, by Application (2019-2030)
11.3.5.3. Market Revenue and Forecast, by End User (2019-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)
11.3.6.2. Market Revenue and Forecast, by Application (2019-2030)
11.3.6.3. Market Revenue and Forecast, by End User (2019-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)
11.3.7.2. Market Revenue and Forecast, by Application (2019-2030)
11.3.7.3. Market Revenue and Forecast, by End User (2019-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)
11.4.2. Market Revenue and Forecast, by Application (2019-2030)
11.4.3. Market Revenue and Forecast, by End User (2019-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)
11.4.4.2. Market Revenue and Forecast, by Application (2019-2030)
11.4.4.3. Market Revenue and Forecast, by End User (2019-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)
11.4.5.2. Market Revenue and Forecast, by Application (2019-2030)
11.4.5.3. Market Revenue and Forecast, by End User (2019-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)
11.4.6.2. Market Revenue and Forecast, by Application (2019-2030)
11.4.6.3. Market Revenue and Forecast, by End User (2019-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)
11.4.7.2. Market Revenue and Forecast, by Application (2019-2030)
11.4.7.3. Market Revenue and Forecast, by End User (2019-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)
11.5.2. Market Revenue and Forecast, by Application (2019-2030)
11.5.3. Market Revenue and Forecast, by End User (2019-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)
11.5.4.2. Market Revenue and Forecast, by Application (2019-2030)
11.5.4.3. Market Revenue and Forecast, by End User (2019-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)
11.5.5.2. Market Revenue and Forecast, by Application (2019-2030)
11.5.5.3. Market Revenue and Forecast, by End User (2019-2030)
Chapter 12. Company Profiles
12.1. F. Hoffmann-La Roche AG
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Bristol-Myers Squibb Company
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. AbbVie, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Johnson & Johnson
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Celgene Corporation
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. AstellasPharma, Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Pfizer, Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Novartis AG
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Merck KGaA
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Eli Lilly and Company
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Why Buy this Report?
The purpose of Precedence Research’s cancer therapeutics market study is to provide stakeholders with a detailed picture of potential barriers and untapped opportunities. The report contains exclusive information to assist businesses in making informed decisions about how to maintain growth throughout the assessment period.
Buy Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1546
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://precedenceresearchnews.wordpress.com
Frequently Asked Questions:
[sc_fs_multi_faq headline-0=”h6″ question-0=”What is the current size of cancer therapeutics market?” answer-0=”According to Precedence Research, the global cancer therapeutics market size was valued at US$ 166.5 billion in 2021 and is expected to reach over US$ 365.99 billion by 2030. ” image-0=”” headline-1=”h6″ question-1=”How much is the CAGR of cancer therapeutics market?” answer-1=”The global cancer therapeutics market is growing at a CAGR of 9.1% over the forecast period 2022 to 2030. ” image-1=”” headline-2=”h6″ question-2=”Who are the major players operating in the cancer therapeutics market?” answer-2=”The major players operating in the cancer therapeutics market are F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, AbbVie, Inc., Johnson & Johnson, Celgene Corporation, AstellasPharma, Inc., Pfizer, Inc., Novartis AG, Merck KGaA, and Eli Lilly and Company. ” image-2=”” headline-3=”h6″ question-3=”Which are the driving factors of the cancer therapeutics market?” answer-3=”The global cancer therapeutics market is propelled by numerous factors such asincrease in cancer prevalence,surge in focus of vendors on the emerging markets,rise in cancer research and surge in collaboration between pharmaceutical companies. ” image-3=”” headline-4=”h6″ question-4=”Which region will lead the global cancer therapeutics market?” answer-4=”North America comprise of a market share of more than 35% in 2020 and will lead the global cancer therapeutics market in near future. ” image-4=”” count=”5″ html=”true” css_class=””]
